Flavopiridol HCl

For research use only.

Catalog No.S2679 Synonyms: NSC 649890 HCl, alvocidib, L86-8275, HMR-1275, DSP-2033

32 publications

Flavopiridol HCl Chemical Structure

CAS No. 131740-09-5

Flavopiridol HCl (NSC 649890 HCl, alvocidib, L86-8275, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 126 In stock
USD 138 In stock
USD 277 In stock
USD 478 In stock
USD 856 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Flavopiridol HCl has been cited by 32 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Flavopiridol HCl (NSC 649890 HCl, alvocidib, L86-8275, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Targets
CDK1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
CDK7 [1]
(Cell-free assay)
40 nM 40 nM 40 nM 40 nM 300 nM
In vitro

Flavopiridol is initially found to inhibit the epidermal growth factor receptor and protein kinase A (IC50 = 21 and 122 μM). Flavopiridol is later shown to inhibit cell proliferation, at more physiologically relevant concentrations (IC50 = 66 nM) when Flavopiridol is tested in the National Cancer Institute Development Therapeutics Program panel of 60 human tumor cell lines. [1] Flavopiridol induces G1 arrest with inhibition of CDK2 and CDK4 in human breast carcinoma cells in a time and concentration dependent manner. [2] Short time treatment of Flavopiridol (~12 hours) induce apoptosis in hematopoietic cell lines including SUDHL4, SUDHL6 (B-cell lines), Jurkat and MOLT4 (T-cell lines ), and HL60 (myeloid). [3] In the clonogenic assay, Flavopiridol functions as a highly potent cytotoxic compound with a mean IC70 with 8 ng/mL in 23 human tumor models. [4] A recent study shows Flavopiridol treatment induces a substantial AKT-Ser473 phosphorylation in human glioblastoma T98G cell line. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 tumor cell NIPZVVNRem:uaX\ldoF1cW:wIHHzd4F6 NWHTdnJZUW6qaXLpeIlwdiCxZjDNR2YuPyC2dX3vdkBk\WyuIIDyc4xq\mW{YYTpc44> MmDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6NEOyNVEoRjFyOESzNlEyRC:jPh?=
Mia PaCa-2 cell NW\Jb5lYTnWwY4Tpc44h[XO|YYm= M1\6OmlvcGmkaYTpc44hd2ZiTXnhJHBiS2FvMjDj[YxtKGOub37v[4VvcWNiYYPzZZktKEmFNUC9N|Yh|ryP MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB4M{[wPUc,OTFyNkO2NFk9N2F-
A2780 cell NYnaR|NTTnWwY4Tpc44h[XO|YYm= NFnGTIVKdmirYnn0bY9vKG:oIFGyO|gxKGOnbHygZ4xwdm:pZX7pZ{Bie3Ojef-8kEBKSzVyPUG1JO69VQ>? NU\kPIJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOlM3ODlpPkGxNFY{PjB7PD;hQi=>
HCT116 cell MlHNSpVv[3Srb36gZZN{[Xl? MVvJcohq[mm2aX;uJI9nKEiFVEGxOkBk\WyuIHPsc45w\2WwaXOgZZN{[XluIFnDOVA:OTNizszN MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB4M{[wPUc,OTFyNkO2NFk9N2F-
PC3 cell NGPCb2VHfW6ldHnvckBie3OjeR?= M2r6T2lvcGmkaYTpc44hd2ZiUFOzJINmdGxiY3zvco9o\W6rYzDhd5NigSxiSVO1NF0yOCEQvF2= M4mzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N|YxQTxxYU6=
K562 human leukemia cell NHnGemFRem:uaX\ldoF1cW:wIHHzd4F6 NFG1ZXpKdmirYnn0bY9vKG:oIFu1OlIhcHWvYX6gcIV2c2WvaXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUCuNVMh|ryP NIPEeo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
MIP human colon carcinoma cell Mke2SpVv[3Srb36gZZN{[Xl? MWXJcohq[mm2aX;uJI9nKE2LUDDoeY1idiClb3zvckBk[XKlaX7vcYEh[2WubDDsbY5mNCCLQ{WwQVAvOTJizszN MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A549 human lung carcinoma cell M3;USHBzd2yrZnXyZZRqd25iYYPzZZk> MlnCTY5pcWKrdHnvckBw\iCDNUS5JIh2dWGwIHz1coch[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF06PiCwTR?= NVn5[YR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
CACO-2 human colon carcinoma cell MVfQdo9tcW[ncnH0bY9vKGG|c3H5 NWP3cFlrUW6qaXLpeIlwdiCxZjDDRWNQNTJiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME24OkBvVQ>? M1jQelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
M109 mouse lung carcinoma cell M1T0b3Bzd2yrZnXyZZRqd25iYYPzZZk> NUHWeXZ[UW6qaXLpeIlwdiCxZjDNNVA6KG2xdYPlJIx2dmdiY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD16MDDuUS=> M1HLSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
A2780/TAX-R human ovarian carcinoma cell NIS1cldRem:uaX\ldoF1cW:wIHHzd4F6 Mo\LTY5pcWKrdHnvckBw\iCDMke4NE9VSVhvUjDoeY1idiCxdnHybYFvKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:Pzhibl2= Mkf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
SKBR-3 human breast carcinoma cell M2HMXnBzd2yrZnXyZZRqd25iYYPzZZk> MlrMTY5pcWKrdHnvckBw\iCVS1LSMVMhcHWvYX6gZpJm[XO2IHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;N{egcm0> M1W1[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
A431 human squamous cell NVnrVFd5WHKxbHnm[ZJifGmxbjDhd5NigQ>? NHHEOHlKdmirYnn0bY9vKG:oIFG0N|EhcHWvYX6gd5F2[W2xdYOgZ4VtdCClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTd3IH7N MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
LX-1 human lung carcinoma NWLhNIxRWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVzzdXZ3UW6qaXLpeIlwdiCxZjDMXE0yKGi3bXHuJIx2dmdiY3HyZ4lvd22jIIDyc4xq\mW{YYTpc44tKEmFNUC9O|Uhdk1? MlrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
MLF mouse lung fibroblast cell NE\O[WFRem:uaX\ldoF1cW:wIHHzd4F6 MlfJTY5pcWKrdHnvckBw\iCPTF[gcY92e2VibIXu[{BncWK{b3LsZZN1KGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF04OiCwTR?= MnfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
PC3 human prostate carcinoma cell MkmzVJJwdGmoZYLheIlwdiCjc4PhfS=> NV\SSWlOUW6qaXLpeIlwdiCxZjDQR|MhcHWvYX6gdJJwe3SjdHWgZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME22OkBvVQ>? MkfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
MCF-7 human breast carcinoma cell MnHHVJJwdGmoZYLheIlwdiCjc4PhfS=> NYjLW|JWUW6qaXLpeIlwdiCxZjDNR2YuPyCqdX3hckBjemWjc4SgZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME22OkBvVQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
LS174T human colon carcinoma cell MWTQdo9tcW[ncnH0bY9vKGG|c3H5 NHyxe3BKdmirYnn0bY9vKG:oIFzTNVc1XCCqdX3hckBkd2yxbjDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPU[1JI5O MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/TAX-S human ovarian carcinoma cell NIPxUHJRem:uaX\ldoF1cW:wIHHzd4F6 M3q2WGlvcGmkaYTpc44hd2ZiQUK3PFAwXEG[LWOgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTZ3IH7N MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/DDP-S human ovarian carcinoma cell MnfSVJJwdGmoZYLheIlwdiCjc4PhfS=> MkDNTY5pcWKrdHnvckBw\iCDMke4NE9FTFBvUzDoeY1idiCxdnHybYFvKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:PTZibl2= M3HvS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
OVCAR-3 human ovarian carcinoma cell MXPQdo9tcW[ncnH0bY9vKGG|c3H5 M{izWGlvcGmkaYTpc44hd2ZiT2\DRXIuOyCqdX3hckBwfmG{aXHuJINiemOrbn;tZUBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9OVQhdk1? Mk\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
CCRF-CEM human leukemia cell M3PaTXBzd2yrZnXyZZRqd25iYYPzZZk> MWLJcohq[mm2aX;uJI9nKEOFUl[tR2VOKGi3bXHuJIxmfWunbXnhJINmdGxicILvcIln\XKjdHnvckwhUUN3ME21NkBvVQ>? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
Hs 27 human fibroblast cell MkL2VJJwdGmoZYLheIlwdiCjc4PhfS=> MYXJcohq[mm2aX;uJI9nKEi|IEK3JIh2dWGwIH\pZpJw[myjc4SgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUWxJI5O NETNbFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
HL60 human leukemia cell NUHQ[nJQWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVTXPW1xUW6qaXLpeIlwdiCxZjDIUFYxKGi3bXHuJIxmfWunbXnhJINmdGxicILvcIln\XKjdHnvckwhUUN3ME20OkBvVQ>? NUewSXBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
ABAE human fibroblast cell MWLQdo9tcW[ncnH0bY9vKGG|c3H5 NGXkV4tKdmirYnn0bY9vKG:oIFHCRWUhcHWvYX6g[oljem:kbHHzeEBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9OFUhdk1? NFvmVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A2780/DDP-R human ovarian carcinoma cell NV;heWd4WHKxbHnm[ZJifGmxbjDhd5NigQ>? NX3TO3VtUW6qaXLpeIlwdiCxZjDBNlc5OC:GRGCtVkBpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;M{igcm0> NWq1WZRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
HCT116/VM46 human colon carcinoma cell MUTQdo9tcW[ncnH0bY9vKGG|c3H5 NIP2R4NKdmirYnn0bY9vKG:oIFjDWFEyPi:YTUS2JIh2dWGwIHPvcI9vKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OjFibl2= NWTFcWFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
HCT116 human colon carcinoma cell Mnm0VJJwdGmoZYLheIlwdiCjc4PhfS=> Ml7sTY5pcWKrdHnvckBw\iCKQ2SxNVYhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD1zODDuUS=> NVTtOGIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
HCT116/VP35 human colon carcinoma cell NHe1cGhRem:uaX\ldoF1cW:wIHHzd4F6 NGnLSJdKdmirYnn0bY9vKG:oIFjDWFEyPi:YUEO1JIh2dWGwIHPvcI9vKGOjcnPpco9u[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OTdibl2= M4LXcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
LNCaP human prostate carcinoma cell NYrBZWN7WHKxbHnm[ZJifGmxbjDhd5NigQ>? NU\od3RyUW6qaXLpeIlwdiCxZjDMUmNiWCCqdX3hckBxem:|dHH0[UBk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9v NG\acWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
human A2780 cell line MVnQdo9tcW[ncnH0bY9vKGG|c3H5 NEK3eoE4OiCq MoHCRY51cXC{b3zp[oVz[XSrdnWg[YZn\WO2IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdCCuaX7lJJdieyCmZYTldo1qdmWmIHnuJIEhf2ixbHWgZ4VtdCB5MjDodkBkgXSxdH;4bYNqfHliYYPzZZktKEmFNUC9O|Ehdk1? NUXFcphtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWwNlc5PjNpPkG1NFI4QDZ|PD;hQi=>
human ovarian (A2780) cancer cell MVnDfZRwfG:6aXRCpIF{e2G7 Mm\YR5l1d3SxeHnjJIVn\mWldDDvckBpfW2jbjDveoFzcWGwIDjBNlc5OCliY3HuZ4VzKGOnbHygcIlv\SxiSVO1NF04OSCwTR?= NUi2clh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxNlU6PzFpPkG1NVI2QTdzPD;hQi=>
ID8 Mk[zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dB?= M3fhWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTWQ5KGOnbHzzMEBKSzVyPUCuNFA4|ryP MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{M{iyNUc,OTdzMkO4NlE9N2F-
MCF7 NUjR[IF4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=> M{jldWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgUWNHPyClZXzsd{whUUN3ME2wMlAzPs7:TR?= NX;rO3hRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlM5OjFpPkG3NVI{QDJzPD;hQi=>
Sf9 NWf2TnhuUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBkgWOuaX6gRU9ETEt{IHX4dJJme3OnZDDpci=> M2raNmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgZ5lkdGmwIFGvR2RMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzMEBKSzVyPUCuNFEz|ryP NIi2NXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mwOFM3Pid-MUe5NFQ{PjZ:L3G+
A2780 MV\Jcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1 Mn7DTY5pcWKrdHnvckBw\iClZHutcYVlcWG2ZXSgUnBOKHCqb4PwbI9zgWyjdHnvckBifCC2aIKxPVkhcW5iaIXtZY4hSTJ5OECgZ4VtdHN? NVvXVGVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
A2780 NETDZ5JKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBT[iCyaH;zdIhwenmuYYTpc44h[XR? M{fYbFI1KGi{cx?= NX7U[4p1UW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhWmJicHjvd5Bpd3K7bHH0bY9vKGG2IITodlgzOSCrbjDoeY1idiCDMke4NEBk\WyuczDh[pRmeiB{NDDodpM> MnzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
A2780 NEXadXhKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBT[iCyaH;zdIhwenmuYYTpc44h[XR? NGDT[VUzPCCqcoO= M4niXmlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJHJjKHCqb4PwbI9zgWyjdHnvckBifCC|ZYK4NFcwQDFzIHnuJIh2dWGwIFGyO|gxKGOnbHzzJIFnfGW{IEK0JIhzew>? NGH4Vm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
A2780 NFr2b3VKdmirYnn0bY9vKG:oIHPkb|kudWWmaXH0[YQhWk6DIIDvcFIhS1SGIIDoc5NxcG:{eXzheIlwdiCjdB?= MlXSNlQhcHK| M3fnfGlvcGmkaYTpc44hd2ZiY3TrPU1u\WSrYYTl[EBTVkFicH;sNkBEXERicHjvd5Bpd3K7bHH0bY9vKGG2IIPldlIhcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhOjRiaILz MoL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
A2780 M3TrNWlvcGmkaYTpc44hd2ZiY3TrO{1u\WSrYYTl[EBTVkFicH;sNkBEXERicHjvd5Bpd3K7bHH0bY9vKGG2 MmnTNlQhcHK| MV3Jcohq[mm2aX;uJI9nKGOma{etcYVlcWG2ZXSgVm5CKHCxbEKgR3RFKHCqb4PwbI9zgWyjdHnvckBifCC|ZYK1JIlvKGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFI1KGi{cx?= NXHUWIhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
A2780 MXXJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmw NXnWcXFbOjRiaILz M4DQTmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO|ZXSgZZMh[XCyZXHyZY5k\SCxZjDNZ4wyKHC{b4TlbY4hdGW4ZXygZYZ1\XJiMkSgbJJ{ NFXle|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
NCI60 NH7Xb2xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 MX:3NkBpenN? MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FSU[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFc1P87:TR?= NHn3OYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFcxOyd-MkGwPFA4ODN:L3G+
NCI60 NUjPXVY6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=> NVzrPG5RPzJiaILz NFPwNZlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTVYxKGOnbHzzJIF{e2W|c3XkJIF{KGyndHjhcEBm\m[nY4SgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEyFNUC9NE46ODUQvF2= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6MEewN{c,OjFyOEC3NFM9N2F-
DR-U2OS-GFP NWD3WZg3WmWmdXP0bY9vKG:oIHjvcY9td2exdYOgdoVkd22kaX7heIlwdiCrbh?= NGrYO|UxNjFidV2= M3;FcFU3KGi{cx?= MmLGVoVlfWO2aX;uJI9nKGixbX;sc4dwfXNicnXjc41jcW6jdHnvckBqdiCqdX3hckBFWi2XMl;TMWdHWCClZXzsd{BmgHC{ZYPzbY5oKElvU3PlTUBvfWOuZXHz[UBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gVmFFPTFibHX2[Ywh[XRiMD6xJJVOKGGodHXyJFU3KGi{czDifUBqdW23bn;icI91fGmwZx?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTRzN{SxO{c,OjF2MUe0NVc9N2F-
A2780 M2DROWN6fG:2b4jpZ4l1gSCjZ3HpcpN1 NEnB[GkzPCCqcoO= MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUCuNFI{|ryP NV7TO4V2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN|AyPzZ5PD;hQi=>
MRC5 Mk\DR5l1d3SxeHnjbZR6KGGpYXnud5Q> NVvabpdtPzJiaILz NHLzUmlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLNUC9NE4xOjkQvF2= NXfIeJJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN|AyPzZ5PD;hQi=>
A2780 NWPPW4QxS3m2b4TvfIlkcXS7IHHnZYlve3R? NU\oOGtpPzJiaILz NGDJdIFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODJ7zszN MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
A2780 M4LJOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1 MYe0PEBpenN? M4rERWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9NE4xOzIQvF2= MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
MRC5 MYXDfZRwfG:6aXPpeJkh[WejaX7zeC=> MYS0PEBpenN? MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGdKPTB;MD6wN|nPxE1? NInDZZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
MRC5 M{L6XmN6fG:2b4jpZ4l1gSCjZ3HpcpN1 M{e0U|I1KGi{cx?= MmPHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUCuNFQ6|ryP MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
HMEC1 MXnDfZRwfG:6aXPpeJkh[WejaX7zeC=> NGLoOYgzPCCqcoO= NHXSdJdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVUWFMTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODZzzszN MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
HMEC1 MnPMR5l1d3SxeHnjbZR6KGGpYXnud5Q> MnG4OFghcHK| NWLqd3VSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUE2HQ{GgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF0xNjB4Mt88US=> MlzpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
HMEC1 NYHOWWNjS3m2b4TvfIlkcXS7IHHnZYlve3R? NEn4PHc4OiCqcoO= M2CxVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhOTUNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLNUC9NE4xPjcQvF2= NH;WO|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
A2780 NWD2SJdHUW6qaXLpeIlwdiCxZjDDSGs6KGmw Ml3pNlQhcHK| M2\GfmlvcGmkaYTpc44hd2ZiQ1TLPUBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhWk6DUFnJJGNVTCCyaH;zdIhwenmuYYTpc44h[XRiU3XyNkBifCCJSUWwJINwdmOnboTyZZRqd25iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
A2780 NGHHT|hE\WyuIHP5Z4xmKGG{cnXzeEBqdg>? MXWyOEBpenN? MVjD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDDs[ZN{KHSqYX6gS2k2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nz M2XqW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
A2780 MU\Jcohq[mm2aX;uJI9nKEOGS{mgbY4> NEPU[5EzPCCqcoO= NUjzUolEUW6qaXLpeIlwdiCxZjDDSGs6KGmwIHj1cYFvKEF{N{iwJINmdGy|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJG1EVDFiYYSgS2k2OCC2bzC1XGdKPTBiY3;uZ4VvfHKjdHnvckBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?= MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
A2780 NI\qZ2hKdmirYnn0bY9vKG:oIFPET|khcW5? MnTuNlQhcHK| MUTJcohq[mm2aX;uJI9nKEOGS{mgbY4hcHWvYX6gRVI4QDBiY3XscJMh[XO|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiSFTNNkBifCCJSUWwJJRwKDW[R1m1NEBkd26lZX70doF1cW:wIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{ Ml;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
A2780 NFTG[WRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnu NHLKWmUzPCCqcoO= NX7ycXllUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gVGFTWCClbHXheoFo\SCjdDDHTVUxKHSxIEXYS2k2OCClb37j[Y51emG2aX;uJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m| NVT2U4NFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN|AyPzZ5PD;hQi=>
MT4 Mn\zRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4S= M4T4UmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCQTDC0MVMhcW6oZXP0[YQhcW5iTWS0JINmdGy|IH3lZZN2emWmIH;uJIRigSB2IIDvd5QhcW6oZXP0bY9vKGK7IICyOEBie3OjeTygSWM2OD1yLkCxOe69VQ>? NVvWdG5IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVQ5ODRpPkK1PVE1QDB2PD;hQi=>
MT4 MXnDfZRwfG:6aXPpeJkh[WejaX7zeC=> MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWFQh[2WubIOsJGlEPTB;MD6wOlfPxE1? NVLKN5hRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVQ5ODRpPkK1PVE1QDB2PD;hQi=>
Sf9 NUPISlIxUW6qaXLpeIlwdiCxZjDDSGszN2O7Y3zpckBGOSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbh?= M4XQVlE2KG2rboO= NGLSfIdKdmirYnn0bY9vKG:oIFPET|Iw[3mlbHnuJGUyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBqdnOnY4SgZ4VtdHNidYPpcochXWyrZ3j0R2ZHU06LVmTQVnRRWFCVUVfLMYFucWSnIIP1ZpN1emG2ZTDh[pRmeiBzNTDtbY5{KGK7IHH1eI9z[WSrb3fyZZBpgSxiSVO1NF0xNjF|zszN M1LONFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG0PFA1Lz5{NUmxOFgxPDxxYU6=
A549 MmrkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dB?= M4DJclMh\GG7cx?= MorGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDNiZHH5d{BjgSCVUlKgcYV1cG:mLDDHTVUxRTBwMUVOwG0> NIXFPIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
DU145 M2nuWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4S= Ml7jN{Bl[Xm| NVHze29RSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjCzJIRigXNiYomgV3JDKG2ndHjv[EwhT0l3ME2wMlE2|ryP MnLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUS4NFQoRjJ3OUG0PFA1RC:jPh?=
KB NWHRXI84SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=> NWrkVpRSOyCmYYnz NXvES3Q1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB|IHThfZMh[nliU2LCJI1mfGixZDygS2k2OD1yLkG2{txO NHrqXGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
KBVIN NXTXXFVISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=> NGDVdW4{KGSjeYO= NULBO2NKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRnZKViClZXzsd{Bi\nSncjCzJIRigXNiYomgV3JDKG2ndHjv[EwhT0l3ME2wMlE5|ryP MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNEiwOEc,OjV7MUS4NFQ9N2F-
HCT116 M4jxNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4S= NGnYPZI4OiCqcoO= NGnpSYZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdHSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDFyJTDm[ZRidCCkb4\pcoUhe2W{dX2sJGVEPTB;MD6wN|TPxE1? M3fSR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUi1N|A2Lz5{Nkm4OVMxPTxxYU6=
HCT116 NVW5PZpRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=> M17ZblczKGi{cx?= NHfsT2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdHSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDBwNkK1KUBn\XSjbDDic5ZqdmVic3XyeY0tKEWFNUC9NE4xPToQvF2= M1zWTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUi1N|A2Lz5{Nkm4OVMxPTxxYU6=
Sf9 MmnsTY5pcWKrdHnvckBw\iCqdX3hci=> NWTMXZFsOTBibXnudy=> MlzXTY5pcWKrdHnvckBw\iCqdX3hckBJcXN4LYTh[4dm\CCFRFu5M4N6[2yrbjDUNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgd4Y6KGOnbHzzJJV{cW6pIFfTWE1EXERiYYOgd5Vje3S{YYTlJIFnfGW{IEGwJI1qdnNiaX6gdJJme2WwY3Wgc4YhY2ejbX3hMVMzWF2DVGCgZpkhW0SVLWDBS2Uh[W6jbInzbZMtKEmFNUC9NE4xODJ3zszN NWfUZY5YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO|ExOzZpPkK3NVcyODN4PD;hQi=>
Sf21 M2fJcmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5? M1qwU2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXN4LYTh[4dm\CCFRFu5M4N6[2yrbjDUNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiUFTLeIll\SCjczDzeYJ{fHKjdHWsJGlEPTB;MD6wNVHPxE1? Mlv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN|YoRjJ5MUexNFM3RC:jPh?=
HeLa M4XJWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1 M3\nXFczKGi{cx?= Mn7BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwQVAvOTMQvF2= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 M3njWGlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5? MojDTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDoeY1idiCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJGNFUzZxTj30[ZJucW6jbDDHV3QufGGpZ3XkJIN6[2yrbjDEN{BmgHC{ZYPz[YQhcW5ic3[yNUBk\WyuczD1d4lv\yCqaYP0c45mKEhzIIP1ZpN1emG2ZTygTWM2OD1yLkO5Oe69VQ>? NF[x[Gc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G3NVA{Pid-MkexO|ExOzZ:L3G+
Sf21 MkPoTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idg>? NIHONlhKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGMufGW{bXnuZYwhUGm|Nj30ZYdo\WRiQ1TLO{9kgWOuaX6gTE9PNXSncn3pcoFtKEeVVD30ZYdo\WRiTVHUNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiY3TrO{B{fWK|dILheIUheGWydHnk[UwhUUN3ME2wMlUyPM7:TR?= NH\DVlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G3NVA{Pid-MkexO|ExOzZ:L3G+
HCT116 M{\ZN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4S= MlX4O|IhcHK| M{fmTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGmwIIDy[ZNmdmOnIH;mJFAvPjJ3JTDGRnMh[W[2ZYKgO|IhcHK|LDDFR|UxRTBwMEW5{txO NULUe|FSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezNlY{OzNpPkK3N|I3OzN|PD;hQi=>
HepG2 MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2 NHL3Rng4OiCqcoO= MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVA:OC5zNE[0{txO M4DZPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO|k4PTxxYU6=
KOPN8 M3vQS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4S= NX\mTHFqPzJiaILz MkDJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNT2DOPEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR|UxRTBwMUmyOu69VQ>? NVvxRXVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
SEM NXHOWZdWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=> NWPqcmFtPzJiaILz NY\YO5R4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcHRqfGW{LVfsc{Bie3OjeTygSWM2OD1yLkKwOFPPxE1? NITq[o09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO|k4PSd-Mkm0NFc6PzV:L3G+
UOCB1 NIPWc3JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 M2DFWVczKGi{cx?= MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFWRQ1KxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVA:OC5{MEi0{txO MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
KOPN8 NYTTVopPUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpci=> MV:wMlUhfU1? Mlm1N{B1dyB{NDDodpM> MVPJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEuRUF64JINmdGy|IHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDjcIVifmWmIGDBVnAhdGW4ZXygZZQhOC53IIXNJIFnfGW{IEOgeI8hOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MmOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O|UoRjJ7NEC3PVc2RC:jPh?=
KOPN8 NX;xXJlFUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpci=> NXnKXI9LOC53IIXN MWmxJIhz M3:xS2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iS1;QUlgh[2WubIOgZZN{\XO|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJINt\WG4ZXSgVGFTWCCuZY\lcEBifCByLkWgeW0heHKnLYTy[YF1\WRid3n0bEBPSUNiZn;yJFEhcHJiYX7kJI1m[XO3cnXkJIFnfGW{IEOgeI8hOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NVPxV|d[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
insect cells NIfRfGpKdmirYnn0bY9vKG:oIHj1cYFv MWmyMlUhdWmwcx?= NYjoeIgxUW6qaXLpeIlwdiCxZjDoeY1idiCFRFu0M4N6[2yrbjDENUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIFnfGW{IEKuOUBucW6|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKGGwYXz5d4l{NCCLQ{WwQVAvODMQvF2= NHTR[|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEezN|A5Pyd-M{C3N|MxQDd:L3G+
TC32 NHThTItyUFSVIHHzd4F6 M1P2TZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| MkjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY NIKwPYxyUFSVIHHzd4F6 Mn;JdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? M2rBbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NFy2XI5yUFSVIHHzd4F6 M2\Gc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NVPITHZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 M3;V[ZFJXFNiYYPzZZk> M2S0cZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MlnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NHe2PYNyUFSVIHHzd4F6 NH\xbGxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NWDlTmpJeUiWUzDhd5NigQ>? NVjjcJJseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 M1fjbJFJXFNiYYPzZZk> M4HtPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 M1SwcJFJXFNiYYPzZZk> MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? NV7lOJJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 MoPqdWhVWyCjc4PhfS=> NEnqdJByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz Mmm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MXnxTHRUKGG|c3H5 Mn35dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NEHGZ5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Caco-2 M4WwS3RwgGmlaYT5JIF{e2G7 NXHoNWl3PDhiaILz Mne5WI95cWOrdImgZYdicW6|dDDDZYNwNTJiY3XscJMh\GW2ZYLtbY5m\CCjdDC0PEBpd3W{czDifUBqdnS{YXPlcIx2dGG{IFHUVEBkd26lZX70doF1cW:wIIXzbY5oKHSqZTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG|c3H5MEBESzVyPUCuNFbPxE1? NHr5Wok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB3Nkm4M{c,S2iHTVLMQE9iRg>?
Caco-2 NX3hTlQ5TnWwY4Tpc44h[XO|YYm= NXGzZXozPDhiaILz NV\FOFBmTGW2ZYLtbY5ifGmxbjDv[kBKSzVyII\hcJVmeyCob4KgbY5pcWKrdHnvckBw\iCVQWLTMWNwXi1{IHnu[JVk\WRiY4n0c5RwgGmlaYT5JI9nKEOjY3:tNkBk\WyuczDh[pRmeiB2ODDoc5VzeyCkeTDobYdpKGOxboTlcpQhcW2jZ3nu[{whUUN3ME2wMlU6|ryP NIPaRpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB3Nkm4M{c,S2iHTVLMQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cleaved caspase-8 / Cleaved caspase-9 / Cleaved caspase-3; 

PubMed: 31193061     


(C) Caspase activation was determined by western blotting. Flavopiridol treatment (300 nM) induced the expressions of cleaved caspase-8, -9 and -3 in a time-dependent manner. 

p-RNAPII / p-eIF4E / Mnk1; 

PubMed: 24572052     


After 24 h drug exposure, CDKI-73 or flavopiridol also abolished p-eIF4E(S209) at 0.25 μM, indicating cellular inhibition of Mnk kinase activity. The same treatment with CDKI-73 or flavopiridol caused a loss in Mnk1 protein expression. CGP57380-treated cells abrogated p-RNAPIIS2 as well as p-eIF4E(S209) with a minimal effect on Mnk1 protein level.

p-ERK / ERK / p-p38 / p-4EBP1 / 4EBP1 / p-S6; 

PubMed: 24572052     


0.25 μM CDKI-73 or flavopiridol caused little changes in the phosphorylation of Erk and p38 MAPK; however, inhibited the 4E-BP1 phosphorylation [p-4E-BP1(Thr70)] by 24 h. CGP57380 had a minimal effect on these proteins.

CDK2 / CDK4 / Cyclin A / p21 / p27 / Rb; 

PubMed: 24572052     


Effect of flavopiridol on cell cycle-related protein expression in uterine leiomyoma cells. Twenty-four hours after treatment, cell extracts were prepared and subjected to immunoblotting analysis. β-Actin was used as an internal loading control.

31193061 24572052
Growth inhibition assay
Cell viability; 

PubMed: 31193061     


The antiproliferative effect of flavopiridol on CCA cell lines was determined using an MTT assay. KKU-055, KKU-100, KKU-213 and KKU-214 cells were treated with 50, 100, 200 or 300 nM of flavopiridol at 24, 48 or 72 h. The percentage of cell number in vehicle control was taken as 100%. Data are mean ± SD of three independent experiments. *P < 0.05 in all CCA cell lines, significantly different for each time point compared with vehicle control.

31193061
In vivo At the maximal tolerated dose of 10 mg/kg/day administered p.o. on days 1-4 and 7-11, Flavopiridol effects tumor regression in PRXF1337 and tumor stasis lasting for 4 weeks in PRXF1369. [4] After treatment with 7.5 mg/kg Flavopiridol bolus intravenous (IV) or intraperitoneal on each of 5 consecutive days, 11 out of 12 advanced stage subcutaneous (s.c.) human HL-60 xenografts undergo complete regressions, and animals remain disease-free several months after one course of Flavopiridol treatment. SUDHL-4 s.c. lymphomas treated with flavopiridol at 7.5 mg/kg bolus IV for 5 days undergo either major (two out of eight mice) or complete (four out of eight mice) regression, with two animals remaining disease-free for more than 60 days. The overall growth delay is 73.2%. Daily IV or IP administration of flavopiridol results in peak plasma levels of about 7 µM, followed by a progressive decline to approximately 100 nM in 8 hours.[6]

Protocol

Kinase Assay:[1]
- Collapse

Recombinant CDKs Kinase Reactions:

CDKs activities are determined in microtiter plates as follows. Forty μg Gst-Rb are mixed with different amounts of Flavopiridol and unlabeled ATP. Reactions are then started by the addition of an ammonium sulfate cut of the S100 fraction obtained from insect cells expressing recombinant human CDKs. The final reaction conditions are 10 mM MgCl2, 50 mM Tris-HCl (pH 7.5), and 1 mM DTT. The final concentration of ATP is adjusted accordingly. Radiolabeled ATP is used as a phosphoryl donor. The reaction is carried out for 2.5 minutes at 30 °C after addition of enzyme and then terminated with the addition of EDTA. The Gst-Rb is then captured with glutathione-Sepharose and the incorporated radioactivity is determined by liquid scintillation counting.
Cell Research:[2]
- Collapse
  • Cell lines: SUDHL4, SUDHL6, Jurkat, MOLT4, and HL60
  • Concentrations: 0, 100 500, 5000 nM
  • Incubation Time: 14 hours
  • Method: Cells grown at a density of 1 × 106 cells/mL are exposed to Flavopiridol for different concentrations and time periods. DNA is extracted. Briefly, cells are washed once with cold phosphate-buffered saline (PBS) and lysed with 3 mL lysis buffer (5 mM Tris-HCL [pH 7.5]; 20 mM EDTA; 0.5% Triton X-100) for 15 minutes at 4 °C. The chromatin of the cell lysates is isolated by centrifugation (20 minutes at 26,000g, 4 °C). The supernatants containing small DNA fragments are extracted sequentially with phenol, phenol:chloroform (1:1), and chloroform. Nucleic acids are precipitated in 0.5 M NaCl, 90% ethanol at -20 °C overnight. RNA is then digested by bovine RNAaseA (60 μg/mL). After sequential reextraction and reprecipitation, DNA is dissolved in 10 mM Tris-HCL (pH 7.5), 1 mM EDTA, 0.5% sodium dodecyl sulfate (SDS) before electrophoresis on 1.6% agarose gel.
    (Only for Reference)
Animal Research:[4] [6]
- Collapse
  • Animal Models: Human prostate cancer xenografts, PRXFI337 and PRXFI369, grown s.c. in nude mice [4] Human promyelocytic leukemia HL-60, human B-cell follicular lymphoma SUDHL-4, and acquired immunodeficiency syndrome (AIDS)-r
  • Dosages: 10 mg/kg/d [4]; 7.5 mg/kg/d [6]
  • Administration: p.o.[4]; i.p. or i.v. [6]
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 88 mg/mL (200.77 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 438.3
Formula

C21H20ClNO5.HCl

CAS No. 131740-09-5
Storage powder
in solvent
Synonyms NSC 649890 HCl, alvocidib, L86-8275, HMR-1275, DSP-2033
Smiles CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00112723 Terminated Drug: alvocidib Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Waldenström Macroglobulinemia National Cancer Institute (NCI) December 2005 Phase 1|Phase 2
NCT00098371 Terminated Drug: alvocidib B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 2
NCT00101231 Terminated Drug: alvocidib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia National Cancer Institute (NCI) October 2004 Phase 1
NCT00058240 Completed Drug: alvocidib B-cell Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2003 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Flavopiridol HCl | Flavopiridol HCl supplier | purchase Flavopiridol HCl | Flavopiridol HCl cost | Flavopiridol HCl manufacturer | order Flavopiridol HCl | Flavopiridol HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID